Anderson Thomas 4

What Happened

• Anderson Thomas, a director of Zevra Therapeutics, received a grant of a derivative award covering 30,000 shares on June 4, 2026. The grant shows $0 paid at issuance (no cash outlay at grant).
• The award is structured with an exercise price equal to the closing price of ZVRA common stock on the Nasdaq Global Select Market on June 4, 2026 (i.e., an at‑the‑market option). The shares are subject to vesting and are awarded as director compensation under the company’s non‑employee director policy.

Key Details

• Transaction date: June 4, 2026; Filing date (Form 4): June 18, 2026 (appears to be filed late relative to the 2-business-day Form 4 deadline).
• Award: 30,000 share‑based derivative units (reported as “A” — grant/award). Amount realized at grant: $0.
• Exercise price: equal to the closing market price on 6/4/2026 (per footnote).
• Vesting: 100% of the shares vest on the earlier of (i) first anniversary of grant, (ii) the day before the first annual stockholders meeting after the grant, or (iii) immediately prior to a change in control — each subject to continued service.
• Shares owned after transaction: not disclosed in the provided filing.
• Purpose: awarded as compensation for board service under the issuer’s non‑employee director compensation policy.

Context

• This is a compensation award (derivative option grant) rather than an open‑market purchase or sale; no immediate cash value was realized by the insider at grant. Such awards are routine for non‑employee directors and do not by themselves indicate a buy or sell signal.
• Because the exercise price matches market price at grant (at‑the‑money), the award’s immediate intrinsic value is zero; future value depends on post‑grant stock performance and vesting conditions.